BioSpace News Archive

Biotech Bay

Roche Makes $290M Investment in Freenome’s Colorectal Cancer Screening Program

Roche’s investment is aimed at supporting the development of Freenome’s colorectal cancer detection technology.

January 11, 2022
·
2 min read
·
Alex Keown
Business

Gameto Nets $20M on Path to Redefining Reproductive Longevity

Gameto has created a three-part platform for ovarian therapeutics that will address menopause and assisted fertility.

January 11, 2022
·
2 min read
·
Kaylei Whalen
Business

Amgen and Arrakis Aim to Destroy Disease with Targeted RNA Degraders

Amgen will partner with Arrakis Therapeutics for an innovative collaboration to research and develop RNA degrader therapeutics.

January 11, 2022
·
2 min read
·
Alvin Clavines
Drug Development

Oh, Where Vaccines Could Take Us

2021 could very well have been “the year of the vaccine.” While this modality is certainly not new, the COVID-19 pandemic is sparking excitement about just what else they might be able to do.

January 11, 2022
·
6 min read
·
Heather McKenzie
Business

Legendary Bayer is Reinventing its Story with Cell and Gene Therapy

Bayer has transformed its pipeline by acquiring multiple cell and gene therapy companies, paving the way for life-saving and life-altering therapies for patients with different disease types.

January 11, 2022
·
4 min read
·
Alex Keown
Business

Nine Square Therapeutics Appoints Robert Paul as CEO

Nine Square Therapeutics announced today that Robert Paul , M.D., Ph.D. , has joined the company as its chief executive officer.

January 11, 2022
·
2 min read
Pharm Country

Clario and XingImaging expand partnership to deliver PET imaging clinical trials in China

Clario and XingImaging have expanded their partnership to deliver PET imaging clinical trials for testing novel therapeutics in China.

January 11, 2022
·
2 min read
Biotech Bay

Significant Investment Accelerates Freenome’s Multiomics Platform for the Early Detection of Cancer

Freenome, a privately held biotech company, announced that Roche has made an investment of $290 million, bringing Freenome’s total funding to more than $1.1 billion since the company was founded in 2014.

January 11, 2022
·
2 min read
Business

Neogene Therapeutics Announces Exclusive License with the National Cancer Institute for a Portfolio of T Cell Receptors (TCR) Targeting KRAS and TP53 Mutations for the Treatment of Cancer

Neogene Therapeutics, Inc. today announced an exclusive, worldwide license agreement with the National Cancer Institute (NCI) for a portfolio of TCRs targeting KRAS and TP53 mutations for the treatment of patients with cancer.

January 11, 2022
·
3 min read
Business

Fusion Pharmaceuticals Announces Research Collaboration with 48Hour Discovery to Develop Peptide-Based Radiopharmaceuticals

Fusion Pharmaceuticals Inc. today announced the company has entered into a strategic research collaboration with 48 Hour Discovery Inc. (48HD) to discover novel, peptide-based radiopharmaceuticals for the treatment of various solid tumors.

January 11, 2022
·
2 min read